Athersys, Inc.
3201 Carnegie Avenue
Cleveland,
OH 44115-2634
United States - Map
Phone: 216-431-9900
Fax: 216-361-9495
Web Site: http://www.athersys.com
| Athersys, Inc., a biopharmaceutical company, engages in the discovery and development of therapeutic product candidates in multiple disease areas in the United States. Its product pipeline includes MultiStem, a nonembryonic stem cell product candidate for the treatment of multiple disease indications. The company also develops orally active pharmaceutical products for the treatment of central nervous system disorders, such as narcolepsy, excessive daytime sleepiness, and chronic fatigue associated with Parkinsons disease; and other potential indications, such as attention deficit hyperactivity disorder and cognitive disorders, which include schizophrenia. In addition, Athersys, Inc., through its product co-development collaboration with Angiotech Pharmaceuticals, Inc., develops MultiStem for the treatment of damage caused by myocardial infarction and peripheral vascular disease, as well as for a range of disease indications, including ischemic injury and cardiovascular disease, certain neurological diseases, autoimmune diseases, transplant support, and various orphan disease indications. The company was founded in 1995 and is based in Cleveland, Ohio. |
|
| Key Statistics |
| |
| | Pay | Exercised | Dr. Gil Van Bokkelen Ph.D, 48
Co-Founder, Chairman and Chief Exec. Officer |
$
370.00K | N/A | Mr. William Lehmann Jr., J.D, 43
Pres, Chief Operating Officer and Sec. |
$
317.00K | N/A | Dr. John J. Harrington Ph.D, 42
Co-Founder, Chief Scientific Officer, Exec. VP |
$
317.00K | N/A | Ms. Laura K. Campbell CPA, 45
Principal Financial Officer, Principal Accounting Officer and VP of Fin. |
$
206.00K | N/A | Dr. Robert J. Deans Ph.D, 58
Sr. VP of Regenerative Medicine |
$
248.00K | N/A |
|
|
|
Dollar amounts are as of
31-Dec-08
and compensation values are for the last fiscal
year ending on that date. "Pay" is salary, bonuses, etc. "Exercised" is the value of
options exercised during the fiscal year.
| |
|
0.29% Nasdaq 
0.01 (0.99%) 
Profile
